Drug intelligence / Profile preview

modified Phl p 1

Development stage
Preclinical
Lead developer
Desentum
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Modified Phl p 1 is a recombinant hypoallergen developed by Desentum for the treatment of grass pollen allergy. It is a genetically engineered version of Phl p 1, the major allergen in Timothy grass (*Phleum pratense*) pollen. The protein has been modified to significantly reduce its IgE-binding capacity, which minimizes the risk of allergic reactions during administration, while preserving the T-cell epitopes necessary to induce long-term immunological tolerance. Intended for subcutaneous immunotherapy (SCIT), the drug aims to provide a safer and more efficient alternative to traditional allergen extracts used in desensitization therapy by promoting the production of protective IgG antibodies and modulating T-cell responses.

Other names
grass pollen hypoallergen (Modified Phl p 1)recombinant Phl p 1 hypoallergenModified Phl p 1
02

Targets

EXPB1 (Group 1 beta-expansin)Phl p 1-specific immunoglobulin ETCR (T cell antigen receptor complex)Phl p (Timothy grass pollen allergen)

Beyond the preview

Go deeper on modified Phl p 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on modified Phl p 1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call